Phosphatidylinositol 3-kinase (PI3K) signaling is critical for the proliferation and survival of malignant B cells. Copanlisib, a pan-class I PI3K inhibitor with predominant activity against PI3K-a and -d isoforms, has demonstrated efficacy and a manageable safety profile in patients with indolent lymphoma.
INTRODUCTION
Malignant lymphomas comprise a heterogeneous group of lymphoproliferative malignancies for which approximately 72,000 new cases and 20,000 deaths were estimated in 2016 in the United States alone. 1 For patients with indolent B-cell lymphoma, first-line therapy usually entails rituximab immunotherapy either alone or combined with chemotherapy such as the alkylating agent bendamustine. 2, 3 However, indolent lymphomas generally are incurable despite initial response to first-line therapy, which commonly precedes relapse and the development of refractory disease for which limited treatment options exist.
Targeted inhibition of phosphatidylinositol 3-kinase (PI3K) has emerged as a therapeutic strategy for patients with relapsed or refractory indolent B-cell lymphoma, 4-6 with the oral PI3K-d isoform inhibitor idelalisib approved in 2014 for third-line treatment of patients with relapsed or refractory follicular lymphoma or small lymphocytic lymphoma. 7 The PI3K-a isoform is expressed to a lesser extent than PI3K-d in various forms of lymphoma, but upregulation of alternative isoforms over time in response to selective PI3K-d inhibition may be a resistance mechanism. [8] [9] [10] Notwithstanding the clinical validation of PI3K-d as a therapeutic target, concerns have emerged about the identified risk of infections, noninfectious pneumonitis, and colitis with oral PI3K-d-targeting agents, such as idelalisib, 11, 12 which highlights the unmet need for active and safe treatment options in patients with relapsed or refractory lymphoma.
Copanlisib (BAY 80-6946; Bayer AG, Berlin, Germany) is an intravenous pan-class I PI3K inhibitor with predominant and potent activity against the PI3K-a and PI3K-d isoforms 13, 14 and has recently been approved by the US Food and Drug Administration for the treatment of patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. Intermittent copanlisib treatment has demonstrated durable responses and a manageable toxicity profile in phase I 15 and phase II 16 studies in patients with relapsed or refractory indolent B-cell lymphoma. In addition, in the previous phase II lymphoma study, a gene expression profile possibly associated with greater response to copanlisib was identified through archival tumor tissues. 16 On the basis of these results, we conducted an open-label phase II study to evaluate the efficacy and safety of copanlisib in patients with relapsed or refractory indolent B-cell lymphoma.
PATIENTS AND METHODS

Study Design
This single-arm, phase II study (ClinicalTrials.gov identifier: NCT01660451 part B; CHRONOS-1 [Open-Label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas]) was conducted at 81 sites across Europe, Asia, the United States, Australia, and New Zealand. Patients received copanlisib 60 mg as a 1-hour infusion on days 1, 8, and 15 of a 28-day cycle. Treatment continued until progression or unacceptable toxicity. The protocol was approved by each study site's independent ethics committee or institutional review board. The study was conducted in accordance with the updated Declaration of Helsinki. All patients provided written informed consent.
Patients
Eligible patients had a histologically confirmed diagnosis of indolent B-cell lymphoma (with histologic subtype that included follicular lymphoma grades 1 to 3a, marginal zone lymphoma [splenic, nodal, or extranodal], small lymphocytic lymphoma [with absolute lymphocyte count , 5 3 10 9 /L], or lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia [with immunoglobulin M paraprotein or . 10% of lymphoplasmacytic cells in bone marrow]). Eligible patients also had relapsed or refractory disease after two or more lines of therapy and had received rituximab and alkylating agents. Additional eligibility criteria included age $ 18 years, one bidimensionally measurable lesion (that was not previously irradiated), 17 and an Eastern Cooperative Oncology Group performance status 18 $ 2. Patients were excluded if they had received prior treatment with PI3K inhibitors or a prior allogeneic bone marrow transplant.
End Points
The primary efficacy end point was objective tumor response rate, which was defined as the proportion of patients who achieved a complete or partial response per central radiologic review. Additional key efficacy end points included duration of response, progression-free survival, overall survival, disease control rate, and best change in target lesions.
Assessments
Tumors were assessed by computed tomography scan or magnetic resonance imaging performed at screening and then every two cycles during year 1, every three cycles during year 2, and every six cycles during year 3. Response was determined by a blinded independent review committee in accordance with the revised International Working Group response criteria for malignant lymphoma. 17 For patients with Waldenström macroglobulinemia, instead of using the response categories published by the Sixth International Workshop on Waldenström's Macroglobulinemia, very good partial response and minor response categories were omitted. 19 A separate secondary analysis also was performed by using the investigator assessments of response.
Clinic visits were scheduled weekly for the first cycle and then weekly for the first 3 weeks of the next cycles, with safety follow-up within 30 to 35 days after the last study treatment; visits were then scheduled every 3 months (6 14 days). Clinic visits included assessment of adverse events (graded by using the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.03]), 20 review of concomitant medications, and physical examination. Noninfectious pneumonitis was captured as a diagnosis for all clinically relevant respiratory events or symptoms, including lung infection and cough, where an infectious etiology could not be clearly identified. Patients were not required to receive prophylaxis for Pneumocystis jirovecii.
Archival formalin-fixed paraffin-embedded tumor tissues were used for mRNA extraction and gene expression profiling with Affymetrix GeneChip Human Gene 1.0 ST Arrays (AltheaDx, San Diego, CA). The Appendix (online only) provides a complete description of gene expression profiling.
Statistical Analysis
Prespecified evaluation of the primary variable was to reject the null hypothesis of an objective response rate of # 40% by using a one-sided exact binomial test with a = 2.5%. Estimates, along with exact 95% CIs after Clopper-Pearson method, were calculated. Time-to-event variables were described by using Kaplan-Meier method. Duration of response was defined as the time from the first observed objective response to first subsequent disease progression or death as a result of disease progression. Progression-free survival was defined as the time from the first administration of study treatment to first disease progression or death as a result of any cause. Patients with no disease progression or who had died were censored at the date of their last tumor assessment. Overall survival was defined as the time from the first administration of study treatment to death as a result of any cause. Overall survival times were censored at the date of the last contact if a patient was lost to follow-up or withdrew consent from the study and follow-up.
Analyses were performed for all patients who received treatment (full analysis set), unless stated otherwise. Statistical analyses were conducted by or under the supervision of the sponsor's study statistician, statistical biomarker expert, and study statistical analyst. Statistical evaluation was performed by using SAS 9.2 software (SAS Institute, Cary, NC) and R version 3.2.3/3.3.0 (The R Foundation, Vienna, Austria).
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Gene set enrichment analysis (GSEA) was performed in all patients with available gene expression data by using gene-specific logistic regression to identify and rank associations with objective response and to develop normalized enrichment scores. 22 Weighted gene expression scores (WGSs) that integrated the overall expression level of each gene signature with its association with objective response to copanlisib were generated per tumor sample by using logistic regression models. The Appendix provides a complete description of the statistical analysis by GSEA and WGS.
RESULTS
Patient Characteristics
Between November 2013 and February 2016, 142 patients were enrolled and started treatment (Appendix Fig A1, online only). The median age of patients was 63 years; 50% were male, and 85% were white ( Table 1) . The majority of patients had follicular lymphoma (73%; n = 104). Most patients (80%; n = 114) had stage III or IV lymphoma, with a median time of 8 weeks since the most recent progression. Patients had received a median of three prior regimens; 86 (61%) had refractory disease after their last regimen. All patients had received prior rituximab and alkylating agents of whom 80 (56%) and 60 (42%), respectively, had refractory disease. One patient with follicular lymphoma who received treatment was later confirmed by the local investigator to have diffuse large B-cell lymphoma.
Efficacy
On the basis of independent blinded central review, the study met its predefined end point with an objective response rate of 59%, which exceeded the prespecified threshold of 40% (95% CI, 51% to 67%; P , .001). Seventeen patients (12%) achieved a complete response and 67 (47%) achieved a partial response (Table 2) . Median time to response was 53 days (range, 41 to 296 days; 95% CI, 51 to 56 days). Forty-three patients (30%) had stable disease, one of whom (1%) had unconfirmed stable disease, and three patients (2%) had progressive disease. Data were not available for 11 patients (8%) and one patient (1%) was not evaluable.
In the 104 patients with follicular lymphoma, the objective response rate was 59%, including 15 patients (14%) with a complete response and 46 (44%) with a partial response ( Table 2 ). The objective response rate was 70% in the 23 patients with marginal zone lymphoma, including two (9%) with a complete response and 14 (61%) with a partial response. Objective response rates of 60% and 57%, respectively, were recorded in patients whose disease was refractory (52 of 86) or responsive (32 of 56) to the last therapy. A waterfall plot of best response in target lesions on the basis of investigator assessment showed that 74 (59%) of the 125 patients assessed had at least a 50% reduction in lesions after treatment with copanlisib (Fig 1) .
Median duration of response was 22.6 months (range, 0 to 22.6 months; Fig 2A) , and responses were rapid and durable during copanlisib treatment (Fig 2B) . Patients with follicular lymphoma had a median duration of response of 12.2 months (range, 0 to 22.6 months; 95% CI, 6.9 to 22.6 months; n = 61). Median progression-free survival was 11.2 months (range, 0.2 to 24.0 months; Fig 2C) , and median overall survival had not yet been reached (Fig 2D) .
Safety Profile
At the time of the database cutoff, median duration of copanlisib treatment was 22 weeks (range, 1 to 105 weeks), with a median duration of safety follow-up of 24 weeks (range, 1 to 104 weeks). Forty-six patients (32%) continued with treatment. Patients received a median of 96% of the planned dose (range, 51 to 103 patients).
Dose delays were experienced in 74% of patients (n = 105), 91% of which were due to adverse events, the majority of which were transient hyperglycemia and transient hypertension and neutropenia. Fifty-five percent of the delays lasted , 1 week (median, 1 week; range, 0 to 3 weeks). Thirty-seven patients (26%) had dose reductions to 45 mg and eight (7%) had dose reductions to 30 mg.
Overall, 140 (99%) of the 142 patients experienced treatmentemergent adverse events of which 53% were grade 3 and 27% were grade 4 (Table 3) . Treatment-related adverse events are summarized in Appendix Table A1 (online only). With the exclusion of transient infusion-related events post hoc, 137 patients (97%) experienced treatment-emergent adverse events of whom 58 (41%) experienced grade 3 events; 29 (20%), grade 4 events; and six (4%), grade 5 events. The most common treatment-emergent adverse events (which occurred in $ 25% of patients) were transient hyperglycemia, transient hypertension, diarrhea, fatigue, decreased neutrophil count, and fever. The highest incidences of grade 3 or 4 events (other than hyperglycemia or hypertension) were decreased †Histology was determined on the basis of investigator assessment. ‡The single patient with DLBCL was initially assessed by the investigator as having indolent non-Hodgkin lymphoma, which was later confirmed by both the investigator and central pathology review to be DLBCL; however, the patient received treatment and was included in the full safety analysis set. §n = 135.
jco.org neutrophil count (8% for grade 3; 16% for grade 4) and lung infection (13% for grade 3; 2% for grade 4). Eleven patients (8%) had noninfectious pneumonitis, with two (1%) experiencing grade 3 events. Serious adverse events of grade $ 3 in three or more patients included lung infection (13%), hyperglycemia (5%), decreased neutrophil count (4%), fever (3%), and diarrhea (2%); two patients had grade 3 pneumonitis, and one patient with a medical history of diverticulosis had grade 4 colitis. Six patients (4%) had grade 5 events during treatment or within 35 days after permanent treatment discontinuation. Three events were considered treatment-related, including lung infection (in one patient with a history of bronchiectasis), respiratory failure (reported to be of multifactorial etiology, including preexisting chronic obstructive pulmonary disease, cardiac failure, and pneumonia), and a cerebral thromboembolic event (in one patient with concurrent atrial fibrillation), and three events were deemed unrelated, including lung infection (in one patient with pneumonia and pleural effusion), acute kidney injury (hydronephrosis secondary to disease progression), and renal failure (secondary to dehydration and contrast dye nephropathy). During the study, three nonfatal opportunistic infections occurred: two P jirovecii infections and one bronchopulmonary aspergillosis infection. Eighteen patients received prophylaxis with sulfamethoxazole and trimethoprim.
Adverse events led to treatment discontinuation in 36 patients (25%) and were considered drug-related in 23 patients (16%), including noninfectious pneumonitis in five (grade 2 or 3, 4%), lung infection in four (grade 2 or 3, 3%), and hyperglycemia in three (grade 4, 2%). Abnormal safety laboratory tests of interest included increased ALT levels (overall, 23%; grade 1, 19%) and 
Abbreviations: FL, follicular lymphoma; LPL/WM, lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma. *One patient with diffuse large B-cell lymphoma was included because the initial investigator assessment was indolent non-Hodgkin lymphoma, which was later confirmed by the investigator and central pathology review to be diffuse large B-cell lymphoma. †Includes one patient with unconfirmed early stable disease (stable disease was assessed , 7 weeks after start of treatment). ‡Of the full analysis set of 142 patients, data for 11 (8%) were not available for the analysis of the primary efficacy variable (objective response rate). §95% CIs by exact binomial calculation. kOne patient with unconfirmed stable disease and four with stable disease or partial response recorded . 35 days from the last treatment were excluded from the calculation. Of the full analysis set of 142 patients, the best change in target lesions for the investigator onsite assessment could not be determined in 15 (11%). In addition, for one patient with follicular lymphoma (with a best response of partial response), best change in target lesions had not been calculated. For one patient classified by the investigator as having follicular lymphoma but who was reclassified by independent assessment as having diffuse large B-cell lymphoma, the change in lesions (increase of 250%) is not shown. (*) Patient was assessed by independent review as having stable disease.
increased AST levels (overall, 28%; grade 1, 25%), which were grade $ 3 in two patients each (Table 3) .
Gene Expression Profiling
Gene expression profiling was performed successfully in 71 patients with indolent lymphoma, including 54 with follicular lymphoma, who were evaluable for response. GSEA showed that upregulation of all five gene sets that reflected PI3K/B-cell receptor (BCR) pathway signaling components (with signatures ranging from 15 to 68 genes) were top-ranked for association with higher response rates in patients with indolent lymphoma and follicular lymphoma, with normalized enrichment scores of 1.93 to 3.09 and 1.52 to 2.64 and false discovery Q = 0 to .003 and 0 to .007, respectively. Higher gene expression levels of PI3K and BCR pathways as assessed by WGS also were associated with higher response rates to copanlisib treatment in patients with indolent lymphoma and follicular lymphoma, with logistic regression nominal P = .009 to .035 and .003 to .229 and areas under the curve of .65 to .71 and .61 to .77, respectively (Fig 3) . A lower macrophage gene expression profile WGS may be associated with higher response rates in indolent lymphoma and follicular lymphoma, with logistic regression nominal P = .098 and .011 and areas under the curve of .62 and .72, respectively. By using the median WGS of the PI3K/BCR pathway gene sets as a cutoff to define elevated expression levels of these pathways, 75% (33 of 44) of patients with indolent lymphoma achieved an objective response, and 86% (six of seven) of those with complete response had elevated PI3K/ BCR profiles. Similarly, 76% (25 of 33) of patients with follicular lymphoma who achieved an objective response and 83% (five of six) of those with a complete response had elevated PI3K/BCR profiles.
DISCUSSION
In this study, treatment with copanlisib showed significant efficacy in heavily pretreated patients with indolent B-cell lymphoma jco.org relapsed or refractory to prior therapy with rituximab and alkylating agents. Overall, 59% of patients achieved an objective response. Responses were rapid and durable, with a median time to response of 53 days and a median duration of response of 22.6 months. Median progression-free survival was 11.2 months, with 46 patients still receiving treatment at the time of database closure. The overall rate of progressive disease as best response was low (2%). Objective responses were observed in 59% of patients with follicular lymphoma and 70% of patients with marginal zone lymphoma, with complete responses observed in both subgroups (14% and 9%, respectively).
These findings are consistent with previous reports of copanlisib in patients with relapsed or refractory indolent B-cell lymphoma. 15, 16 The current efficacy data for copanlisib also are consistent with those reported for the PI3K-d-selective inhibitor idelalisib, which has a demonstrated objective response rate of 57% in patients with relapsed indolent lymphoma and 56% in a follicular lymphoma subset (median duration of response, 12.5 and 10.8 months, respectively) and overall progression-free survival of 11.0 months.
4,23 The PI3K-d and -g dual inhibitor duvelisib has been reported to show an objective response rate of 46% and median progression-free survival of 8.4 months. 24 The response rate of copanlisib was also greater than that reported in small cohorts of patients with relapsed or refractory indolent lymphoma for the pan-PI3K inhibitor pilaralisib 25 and the Bruton's tyrosine kinase inhibitor ibrutinib. 26 However, because of differences between trials, response rates should be interpreted with caution. The pan-PI3K inhibitors buparlisib and pictilisib have not been evaluated beyond phase I in patients with indolent B-cell lymphoma. 27, 28 Durable responses were observed in patients who had received multiple prior lines of therapy, including rituximab and alkylating agents, which suggests that PI3K activation may play a critical oncogenic role in malignant B-cell lymphoma. These results also are consistent with the identification of a gene expression profile first observed in a small number of patients with indolent and aggressive lymphomas, 16 are validated in the current study, and show that patients with indolent lymphoma with activated PI3K/ BCR signaling and low stromal/macrophage gene activity are more likely to respond to copanlisib.
Transient hyperglycemia was the most common treatmentrelated adverse event, which occurred in 49% of patients, with 41% grade 3 (. 250 mg/dL) or 4, although it was largely self-limiting and did not lead to significant treatment discontinuation. Hyperglycemia is a recognized on-target effect of PI3K-a inhibition that is related to insulin receptor signaling and results in transiently reduced use of tissue glucose and/or insulin resistance.
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The incidence of hyperglycemia reported here was consistent with previous reports of copanlisib 15, 16 and other pan-PI3K inhibitors.
25,27,28 However, only a few cases of hyperglycemia required more intensive management, such as in patients who experienced symptoms or who were diabetic for whom short-acting (regular) insulin was recommended. General recommendations for the management of treatment-related hyperglycemia are provided in the Appendix.
Transient hypertension occurred in 30% of patients, with 24% grade 3 (. 160 mm Hg). However, as with hyperglycemia, this was not a significant cause for treatment discontinuation.
A lower incidence of severe GI toxicities, such as hepatic transaminitis, diarrhea, colitis, or colonic perforations (none observed), were seen with intermittent intravenous copanlisib treatment compared with previous reports with continuous oral idelalisib treatment, 4 which suggests that both route of administration and dosing schedule may be important. More recently, increased rates of infectious and autoimmune toxicities, including deaths, in trials that combined idelalisib with other agents led to the termination of clinical studies and recommendations for careful monitoring of patients.
11,12 In the current study, fewer such adverse events were observed with copanlisib monotherapy. Studies that combine copanlisib with standard immunochemotherapy in patients with indolent lymphoma are ongoing (ClinicalTrials.gov identifiers: NCT02367040 and NCT02626455).
In conclusion, treatment with copanlisib results in significant and durable responses in heavily pretreated patients with relapsed or refractory indolent lymphoma. In addition, copanlisib has a manageable safety profile in this population, with low rates of severe hepatic transaminitis, diarrhea, colitis, and noninfectious pneumonitis. Opportunistic infections, fatal infections, and other fatal adverse events were infrequent. Taken together, the results indicate a favorable risk-benefit profile that supports the use of copanlisib treatment in this clinical setting. cover postprandial glucose increases on subsequent infusion days was recommended for patients who had required insulin postinfusion on the previous infusion day and for patients whose glucose values were . 200 mg/dL on more than one occasion postinfusion. Potential oral glucose-lowering agents were metformin (500 mg at 15 minutes premeal as a starting dose), a glucose cotransporter 2 inhibitor (that started with a morning preinfusion dose), and a dipeptidyl peptidase-4 inhibitor (that started with a morning preinfusion dose). Combinations of insulin and an oral glucose-lowering drug or combinations of oral glucose-lowering agents generally were not recommended because of the potential for hypoglycemia. The use of sulphonylurea/meglitinide medications to manage glucose after copanlisib infusions was not recommended. 
